Salt Bridging study for GSK961081
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Enrollment
18
GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
GSK Investigational Site
London, United Kingdom
FEV1 at intervals
Time frame: during the 10 week study
Cardiac monitoring at intervals
Time frame: during the 10 week study
Plasma concentrations of GSK961081 at intervals
Time frame: during the 10 week study
PK parameters at intervals
Time frame: during the 10week study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.